{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Maravai Lifesciences Holdings, Inc.
Maravai Lifesciences Hits New 52-Week High at $7.25
Maravai Lifesciences Holdings, Inc. recently achieved a new 52-week high, highlighting its position in the Pharmaceuticals & Biotechnology industry. Despite this milestone, the company has experienced a decline in its one-year performance and currently operates at a loss, with a market capitalization of USD 735 million.
Maravai Lifesciences Hits New 52-Week High at $6.54
Maravai Lifesciences Holdings, Inc. achieved a new 52-week high, marking a significant milestone for the small-cap company in the Pharmaceuticals & Biotechnology sector. Despite recent stock price gains, the company has faced challenges, including a notable decline in performance over the past year and ongoing financial losses.
Maravai Lifesciences Hits New 52-Week High of $6.21
Maravai Lifesciences Holdings, Inc. achieved a new 52-week high of USD 6.21, marking a significant milestone for the small-cap biotechnology firm. Despite this recent increase, the company's one-year performance shows a decline, with financial metrics indicating ongoing losses and a moderate level of leverage.
Maravai Lifesciences Hits New 52-Week High at $5.42
Maravai Lifesciences Holdings, Inc. achieved a new 52-week high of USD 5.42, marking a significant milestone for the microcap company in the Pharmaceuticals & Biotechnology sector. Despite this recent increase, the company has experienced a decline in its one-year performance, reflecting ongoing challenges in the industry.
Maravai Lifesciences Hits New 52-Week High of $5.29, Marking Significant Milestone
Maravai Lifesciences Holdings, Inc. achieved a new 52-week high of USD 5.29 on June 10, 2026, despite a one-year decline of 39.74%. The company, with a market cap of USD 735 million, is currently loss-making and focuses on growth without offering dividends.
Maravai Lifesciences Stock Forms Golden Cross, Signals Bullish Breakout Ahead
Maravai Lifesciences Holdings, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Despite a challenging year, the stock has shown resilience with a notable monthly increase, outperforming the S&P 500. Technical indicators suggest a bullish sentiment, attracting investor interest in the biotechnology sector.
Is Maravai Lifesciences Holdings, Inc. technically bullish or bearish?
As of September 11, 2025, Maravai Lifesciences Holdings, Inc. is in a mildly bearish trend, with daily moving averages indicating bearishness, while its year-to-date return is -47.16%, significantly underperforming the S&P 500's 12.22%.
Is Maravai Lifesciences Holdings, Inc. overvalued or undervalued?
As of February 22, 2024, Maravai Lifesciences Holdings, Inc. is considered risky and overvalued with poor financial metrics and a year-to-date stock performance of -47.16%, significantly underperforming compared to the S&P 500's 12.22% return.
Is Maravai Lifesciences Holdings, Inc. overvalued or undervalued?
As of February 22, 2024, Maravai Lifesciences Holdings, Inc. is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 2.02, an EV to Sales ratio of 2.56, and poor performance indicators like a -27.14% ROCE and -34.98% ROE, alongside a year-to-date stock return of -61.28% compared to the S&P 500's 2.44%.
Is Maravai Lifesciences Holdings, Inc. technically bullish or bearish?
As of June 20, 2025, Maravai Lifesciences Holdings, Inc. is in a bearish trend with moderate strength, indicated by daily moving averages and Bollinger Bands, despite some mixed signals from MACD and KST.
What does Maravai Lifesciences Holdings, Inc. do?
Maravai Lifesciences Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $47 million and a net loss of $53 million as of March 2025. The company has a market cap of $532.24 million and no dividend yield.
How big is Maravai Lifesciences Holdings, Inc.?
As of Jun 18, Maravai Lifesciences Holdings, Inc. has a market capitalization of 532.24 million, with net sales of 241.86 million and a net profit of -289.79 million over the latest four quarters. The company's shareholder's funds are 325.29 million, and total assets amount to 1,008.24 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
